Treatment of inclusion-body myositis with IVIg: A double-blind, placebo- controlled study

Marinos C. Dalakas, B. Sonies, J. Dambrosia, Elizabeth Sekul, E. Cupler, K. Sivakumar

Research output: Contribution to journalArticle

267 Citations (Scopus)

Abstract

We randomized 19 patients with inclusion-body myositis (IBM) to a double-blind, placebo-controlled, crossover study using monthly infusions of 2 g/kg intravenous immunoglobulin (IVIg) or placebo for 3 months. Patients crossed over to the alternate treatment after a washout period. We evaluated responses at baseline and at the end of each treatment period using expanded (0-10) MRC scales, the Maximum Voluntary Isometric Contraction (MVIC) method, symptom and disability scores, and quantitative swallowing studies. We calculated the differences in scores between IVIg and placebo from baseline to end of treatment. Of the 19 patients, 9 (mean age, 61.2 years; mean disease duration, 5.6 years) were randomized to IVIg and 10 (mean age, 66.1 years; mean disease duration, 7.4 years) to placebo. During IVIg the patients gained a mean of 4.2 (-16 to +39.8) MRC points, and during placebo lost 2.7 (-10 to +8) points (p < 0.1). These gains were not significant. Similar results were obtained with the MRC and MVIC scores when the patients crossed to the alternate treatment. Six patients had a functionally important improvement by more than 10 MRC points that declined when crossed over to placebo. Limb-by-limb analysis demonstrated that during IVIg the muscle strength in 39% of the lower extremity limbs significantly increased compared with placebo (p < 0.05), while a simultaneous decrease in 28% of other limbs was detected. The clinical importance of these minor gains is unclear. The duration of swallowing functions measured in seconds with ultrasound improved statistically in the IVIg-randomized patients (p < 0.05) compared with placebo. Although the study did not establish efficacy of IVIg, possibly because of the small sample size, the drug induced functionally important improvement in 6 (28%) of the 19 patients. Whether the modest gains noted in certain muscle groups justify the high cost of trying IVIg in IBM patients at a given stage of the disease remains unclear.

Original languageEnglish (US)
Pages (from-to)712-716
Number of pages5
JournalNeurology
Volume48
Issue number3
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Inclusion Body Myositis
Intravenous Immunoglobulins
Immunoglobulin A
Placebos
Isometric Contraction
Therapeutics
Extremities
Deglutition
Lower Extremity
Muscle Strength
Sample Size
Cross-Over Studies

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Dalakas, M. C., Sonies, B., Dambrosia, J., Sekul, E., Cupler, E., & Sivakumar, K. (1997). Treatment of inclusion-body myositis with IVIg: A double-blind, placebo- controlled study. Neurology, 48(3), 712-716. https://doi.org/10.1212/WNL.48.3.712

Treatment of inclusion-body myositis with IVIg : A double-blind, placebo- controlled study. / Dalakas, Marinos C.; Sonies, B.; Dambrosia, J.; Sekul, Elizabeth; Cupler, E.; Sivakumar, K.

In: Neurology, Vol. 48, No. 3, 01.01.1997, p. 712-716.

Research output: Contribution to journalArticle

Dalakas, MC, Sonies, B, Dambrosia, J, Sekul, E, Cupler, E & Sivakumar, K 1997, 'Treatment of inclusion-body myositis with IVIg: A double-blind, placebo- controlled study', Neurology, vol. 48, no. 3, pp. 712-716. https://doi.org/10.1212/WNL.48.3.712
Dalakas, Marinos C. ; Sonies, B. ; Dambrosia, J. ; Sekul, Elizabeth ; Cupler, E. ; Sivakumar, K. / Treatment of inclusion-body myositis with IVIg : A double-blind, placebo- controlled study. In: Neurology. 1997 ; Vol. 48, No. 3. pp. 712-716.
@article{89203305a0e34df6bae59e2dea5fe376,
title = "Treatment of inclusion-body myositis with IVIg: A double-blind, placebo- controlled study",
abstract = "We randomized 19 patients with inclusion-body myositis (IBM) to a double-blind, placebo-controlled, crossover study using monthly infusions of 2 g/kg intravenous immunoglobulin (IVIg) or placebo for 3 months. Patients crossed over to the alternate treatment after a washout period. We evaluated responses at baseline and at the end of each treatment period using expanded (0-10) MRC scales, the Maximum Voluntary Isometric Contraction (MVIC) method, symptom and disability scores, and quantitative swallowing studies. We calculated the differences in scores between IVIg and placebo from baseline to end of treatment. Of the 19 patients, 9 (mean age, 61.2 years; mean disease duration, 5.6 years) were randomized to IVIg and 10 (mean age, 66.1 years; mean disease duration, 7.4 years) to placebo. During IVIg the patients gained a mean of 4.2 (-16 to +39.8) MRC points, and during placebo lost 2.7 (-10 to +8) points (p < 0.1). These gains were not significant. Similar results were obtained with the MRC and MVIC scores when the patients crossed to the alternate treatment. Six patients had a functionally important improvement by more than 10 MRC points that declined when crossed over to placebo. Limb-by-limb analysis demonstrated that during IVIg the muscle strength in 39{\%} of the lower extremity limbs significantly increased compared with placebo (p < 0.05), while a simultaneous decrease in 28{\%} of other limbs was detected. The clinical importance of these minor gains is unclear. The duration of swallowing functions measured in seconds with ultrasound improved statistically in the IVIg-randomized patients (p < 0.05) compared with placebo. Although the study did not establish efficacy of IVIg, possibly because of the small sample size, the drug induced functionally important improvement in 6 (28{\%}) of the 19 patients. Whether the modest gains noted in certain muscle groups justify the high cost of trying IVIg in IBM patients at a given stage of the disease remains unclear.",
author = "Dalakas, {Marinos C.} and B. Sonies and J. Dambrosia and Elizabeth Sekul and E. Cupler and K. Sivakumar",
year = "1997",
month = "1",
day = "1",
doi = "10.1212/WNL.48.3.712",
language = "English (US)",
volume = "48",
pages = "712--716",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Treatment of inclusion-body myositis with IVIg

T2 - A double-blind, placebo- controlled study

AU - Dalakas, Marinos C.

AU - Sonies, B.

AU - Dambrosia, J.

AU - Sekul, Elizabeth

AU - Cupler, E.

AU - Sivakumar, K.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - We randomized 19 patients with inclusion-body myositis (IBM) to a double-blind, placebo-controlled, crossover study using monthly infusions of 2 g/kg intravenous immunoglobulin (IVIg) or placebo for 3 months. Patients crossed over to the alternate treatment after a washout period. We evaluated responses at baseline and at the end of each treatment period using expanded (0-10) MRC scales, the Maximum Voluntary Isometric Contraction (MVIC) method, symptom and disability scores, and quantitative swallowing studies. We calculated the differences in scores between IVIg and placebo from baseline to end of treatment. Of the 19 patients, 9 (mean age, 61.2 years; mean disease duration, 5.6 years) were randomized to IVIg and 10 (mean age, 66.1 years; mean disease duration, 7.4 years) to placebo. During IVIg the patients gained a mean of 4.2 (-16 to +39.8) MRC points, and during placebo lost 2.7 (-10 to +8) points (p < 0.1). These gains were not significant. Similar results were obtained with the MRC and MVIC scores when the patients crossed to the alternate treatment. Six patients had a functionally important improvement by more than 10 MRC points that declined when crossed over to placebo. Limb-by-limb analysis demonstrated that during IVIg the muscle strength in 39% of the lower extremity limbs significantly increased compared with placebo (p < 0.05), while a simultaneous decrease in 28% of other limbs was detected. The clinical importance of these minor gains is unclear. The duration of swallowing functions measured in seconds with ultrasound improved statistically in the IVIg-randomized patients (p < 0.05) compared with placebo. Although the study did not establish efficacy of IVIg, possibly because of the small sample size, the drug induced functionally important improvement in 6 (28%) of the 19 patients. Whether the modest gains noted in certain muscle groups justify the high cost of trying IVIg in IBM patients at a given stage of the disease remains unclear.

AB - We randomized 19 patients with inclusion-body myositis (IBM) to a double-blind, placebo-controlled, crossover study using monthly infusions of 2 g/kg intravenous immunoglobulin (IVIg) or placebo for 3 months. Patients crossed over to the alternate treatment after a washout period. We evaluated responses at baseline and at the end of each treatment period using expanded (0-10) MRC scales, the Maximum Voluntary Isometric Contraction (MVIC) method, symptom and disability scores, and quantitative swallowing studies. We calculated the differences in scores between IVIg and placebo from baseline to end of treatment. Of the 19 patients, 9 (mean age, 61.2 years; mean disease duration, 5.6 years) were randomized to IVIg and 10 (mean age, 66.1 years; mean disease duration, 7.4 years) to placebo. During IVIg the patients gained a mean of 4.2 (-16 to +39.8) MRC points, and during placebo lost 2.7 (-10 to +8) points (p < 0.1). These gains were not significant. Similar results were obtained with the MRC and MVIC scores when the patients crossed to the alternate treatment. Six patients had a functionally important improvement by more than 10 MRC points that declined when crossed over to placebo. Limb-by-limb analysis demonstrated that during IVIg the muscle strength in 39% of the lower extremity limbs significantly increased compared with placebo (p < 0.05), while a simultaneous decrease in 28% of other limbs was detected. The clinical importance of these minor gains is unclear. The duration of swallowing functions measured in seconds with ultrasound improved statistically in the IVIg-randomized patients (p < 0.05) compared with placebo. Although the study did not establish efficacy of IVIg, possibly because of the small sample size, the drug induced functionally important improvement in 6 (28%) of the 19 patients. Whether the modest gains noted in certain muscle groups justify the high cost of trying IVIg in IBM patients at a given stage of the disease remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=0030947027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030947027&partnerID=8YFLogxK

U2 - 10.1212/WNL.48.3.712

DO - 10.1212/WNL.48.3.712

M3 - Article

C2 - 9065553

AN - SCOPUS:0030947027

VL - 48

SP - 712

EP - 716

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -